Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

Barré for every million doses given.

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

智通财经APP获悉，据知情人士透露，葛兰素史克(GSK.US)正在就收购生物技术公司IDRx进行谈判，对后者的估值可能高达10亿美元。知情人士补充称，谈判仍在进行中，不能保证会达成协议。据悉，IDRx正在开发一种用于胃肠道间质瘤的实验性药物。这笔交易 ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

The move will place students in good stead to take up skilled roles in biopharma manufacturing. Read more at straitstimes.com ...

Ken Hall looks at two big investment risks that are keeping him up at night as we enter 2025 with the UK stock market ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...